Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Champions Oncology (CSBR) Accumulated Depreciation & Amortization (2016 - 2026)

Champions Oncology has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $341000.0 for Q1 2026.

  • Quarterly results put Accumulated Depreciation & Amortization at $341000.0 for Q1 2026, down 14.32% from a year ago — trailing twelve months through Jan 2026 was $341000.0 (down 14.32% YoY), and the annual figure for FY2025 was $1.6 million, down 12.16%.
  • Accumulated Depreciation & Amortization for Q1 2026 was $341000.0 at Champions Oncology, down from $715000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CSBR hit a ceiling of $2.2 million in Q2 2023 and a floor of $341000.0 in Q1 2026.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $715000.0 (2025), compared with a mean of $983058.8.
  • Peak annual rise in Accumulated Depreciation & Amortization hit 79.2% in 2025, while the deepest fall reached 71.77% in 2025.
  • Champions Oncology's Accumulated Depreciation & Amortization stood at $560000.0 in 2022, then soared by 65.89% to $929000.0 in 2023, then plummeted by 57.05% to $399000.0 in 2024, then surged by 79.2% to $715000.0 in 2025, then tumbled by 52.31% to $341000.0 in 2026.
  • The last three reported values for Accumulated Depreciation & Amortization were $341000.0 (Q1 2026), $715000.0 (Q4 2025), and $358000.0 (Q3 2025) per Business Quant data.